Entia Biosciences Inc (ERGO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2009 | 03-2009 | |
| Cash Flows From Operating Activities | ||
| Net Income | -236 | -150 |
| Accounts payable and accrued liabilities | N/A | -14 |
| Other Working Capital | 25 | 19 |
| Other Operating Activity | 6 | 16 |
| Operating Cash Flow | $-204 | $-129 |
| Cash Flows From Investing Activities | ||
| PPE Investments | -4 | -3 |
| Other Investing Activity | -162 | -165 |
| Investing Cash Flow | $-166 | $-168 |
| Cash Flows From Financing Activities | ||
| Common Stock Issued | 498 | 135 |
| Other Financing Activity | -26 | -6 |
| Financing Cash Flow | $471 | $129 |
| Beginning Cash Position | 273 | 273 |
| End Cash Position | 374 | 105 |
| Net Cash Flow | $101 | $-168 |
| Free Cash Flow | ||
| Operating Cash Flow | -204 | -129 |
| Capital Expenditure | -4 | -3 |
| Free Cash Flow | -208 | -132 |